ESR2 and cancer: In the second group of patients with low ERβ expression, even though the expression of ERα remained negative, the risk was increased by 14% for overall mortality and 33% for cancer recurrence compared to patients with combined high ERβ negative ERα expression (Supplementary Table 1).